New combo targets pancreatic Cancer's DNA repair
NCT ID NCT01489865
First seen Nov 06, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tested a new combination of drugs (ABT-888 plus chemotherapy) in 64 people with pancreatic cancer that had spread. The goal was to see if adding ABT-888, which blocks cancer cells from repairing damage, could shrink tumors better than chemo alone. Participants had to have a specific genetic mutation or family history linked to breast or ovarian cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
Conditions
Explore the condition pages connected to this study.